Diane K. Jorkasky, M.D. FACP is a highly regarded pharmaceutical industry executive with a broad background across research and all phases of clinical development in multiple therapeutic areas with affinity for translational clinical pharmacology. Dr. Jorkasky is an Expert Consultant for NDA Partners and serves as an Independent Director on the Boards of Alzheon, Inc. and Altimmune, Inc. She has been a long-serving member of the Executive Steering Committee of the American Course of Drug Development and Regulatory Sciences and conducts the sessions on translational pharmacology. Prior to her current roles, she was Chief Medical Officer of Complexa Inc., Endo Pharmaceuticals, and Aileron Therapeutics. Her experience also includes executive positions with Pfizer as its Vice President of Global Clinical Research Operations, where she was responsible for all exploratory development, clinical pharmacology, and translational medicine. Of her many accomplishments, she led Pfizer’s international Clinical Research Units which received certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry or academia to achieve such a recognition. Previously, Dr. Jorkasky was Vice President of Clinical Research at SmithKline Beecham, and Chief of Nephrology at Presbyterian-Penn Medical Center in Philadelphia.
Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology, having completed her medical and fellowship training at the University of Pennsylvania School of Medicine (Philadelphia, PA). She is on the faculties of University of California, San Francisco, and the Uniformed Service of Health Sciences Medical School (Bethesda, MD).